

Albumin Market Report and Forecast 2025-2034

Market Report | 2025-07-29 | 350 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4949.00
- Five User License \$5949.00
- Corporate License \$6969.00

Report description:

The global albumin market value in 2024 was USD 5.63 Billion and is anticipated to grow at a CAGR of 6.20% during the forecast period of 2025-2034, driven by the growing demand for albumin-based drug formulations across the globe. The global albumin market size is anticipated to reach a value of USD 10.27 Billion by 2034.

Global Albumin Market Overview

Albumin is the most abundant plasma protein in adult humans, representing 50% of the total protein content of the plasma. The protein has a half-life of 21 days, with a concentration ranging from 35 to 59 g/L in the blood plasma. Albumin is synthesized by the liver at the rate of 10-15 grams per day. It has approximately 100 variant forms and plays an important role in maintaining the oncotic pressure to prevent the leaking of fluids into the extravascular space.

Albumin plays several physiological roles. It is accountable for maintaining 80% of the colloid osmotic pressure. A decrease in the level of serum albumin causes hypoalbuminemia, which is one of the most prevalent disorders in hospitalized and critically ill patients. Hypoalbuminemia has a prevalence rate of ~70% in elderly hospitalized patients. Thus, the rising incidence of hypoalbuminemia is one of the key factors driving the albumin market growth.

The market is further boosted by the rising liver and cardiovascular disorders, which makes individuals prone to a low albumin levels in the body. In addition, the therapeutic and non-therapeutic applications of human serum albumin are propelling the market demand.

Technological Developments Expediting Albumin-Based Drug Delivery System

Albumin has become a popular delivery carrier for hydrophobic drugs due to advancements in nanotechnology. The surge in clinical applications is expected to boost the albumin market share in the forecast period. Owing to its unique chemical structure, albumin allows effective interaction with many drugs and protects them from elimination in vivo. In May 2023, reverse QTY (rQTY)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

code was utilized to design amphiphilic human serum albumin (HAS) proteins, which resolved the problem of protein denaturation at the time of drug loading. Additionally, the HAS rQTY variants exhibited superior biological activities like tumor cell-targeting as compared to the denatured HAS nanoparticles. Such technological advancements in the drug development sector are bolstering the demand for albumin in the pharmaceutical industry.

Rise in Funding and Investment to Meet Albumin Market Demand

The pharmacokinetic and pharmacodynamic profile of albumin makes it an effective drug carrier. To exploit its versatility as a protein delivery vehicle, there has been increased funding and investment in the albumin market. In December 2023, an Indian biopharmaceutical startup, PlasmaGen Biosciences raised around USD 27 million via equity funding to accelerate the growth of blood plasma-based products such as albumin. The company received major financing from Artian Investments (an investment management firm based in the United Kingdom) and other prominent investors.

Another major investment boosting the albumin market value was witnessed when SK Plasma, a South Korean developer of plasma-derived medicine, received USD 50 million from the Indonesia Investment Authority (INA), a government-owned sovereign wealth fund in October 2023. The funds will be used to build a plasma fractionation plant for manufacturing blood products such as albumin and immunoglobulin. Expected to be built by 2025, the facility is projected to process a million liters of raw plasma every year. The growing investments in the albumin market are anticipated to increase the market size in the coming years.

Global Albumin Market Segmentation

The EMR's report titled "Albumin Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:

Market Breakup by Product

- Human Serum Albumin
- Recombinant Albumin
- Bovine Serum Albumin

Market Breakup by Application

- Drug Delivery
- Therapeutics
- Vaccine Ingredient
- Culture Media Diagnostics

Market Breakup by End User

- Hospitals & Clinics
- Pharmaceutical & Biotechnology Industry
- Research Institutes

Market Breakup by Region

- North America
- Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Asia Pacific
- Latin America
- Middle East and Africa

Global Albumin Market Regional Analysis

In North America, the market growth of albumin is driven by the rising research and development activities for expanding the clinical applications of human, bovine, and recombinant serum albumin. Technological advancements in protein purification and molecular separation technology are anticipated to boost market growth.

Europe holds a significant albumin market share, owing to the presence of top healthcare companies in the region. Moreover, the rising focus of government on the development of albumin-derived pharmaceuticals is propelling market growth. In June 2023, the health authority in the United Kingdom, the Medicines and Healthcare Products Regulatory Agency (MHRA) lifted the ban on the use of blood plasma from donors of the United Kingdom to derive albumin. The authorization to use UK donor plasma to manufacture albumin treatments is expected to aid in the expansion of the albumin market in the region.

Global Albumin Market: Competitor Landscape

The expansion of manufacturing capacities and capabilities by the leading healthcare companies to accommodate the growing demand for albumin is one of the major market trends. In June 2023, Thermo Fisher Scientific, a biotechnology company based in the United States developed a 'Biologics Manufacturing Facility' covering an area of 1.5 million square feet in Switzerland. Thermo Fisher Scientific, along with their strategic partner CSL Limited (a global biotechnology company) will use the facility to produce Idelvion, a next-generation hemophilia product having recombinant albumin as an essential component, among other things. The growing demand for albumin in the development of drugs is expected to increase the albumin market size in the forecast period.

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Alumedix
- Albumin Therapeutics, LLC
- Biotest AG
- CSL
- Grifols, S.A.
- HiMedia Laboratories
- Invitria
- Medxbio Pte Ltd.
- Octapharma AG
- RayBiotech, Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- SeraCare
- Merck KGaA
- Takeda Pharmaceutical Company Limited
- Kedrion S.p.A.
- Aspira

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Albumin Market Overview
 - 3.1 Global Albumin Market Historical Value (2018-2024)
 - 3.2 Global Albumin Market Forecast Value (2025-2034)
- 4 Global Albumin Market Landscape*
 - 4.1 Global Albumin Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Albumin Product Landscape
 - 4.2.1 Analysis by Product
 - 4.2.2 Analysis by Application
- 5 Global Albumin Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Model
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Albumin Market Segmentation (218-2034)
 - 6.1 Global Albumin Market (2018-2034) by Product
 - 6.1.1 Market Overview
 - 6.1.2 Human Serum Albumin
 - 6.1.3 Recombinant Albumin
 - 6.1.4 Bovine Serum Albumin
 - 6.2 Global Albumin Market (2018-2034) by Application
 - 6.2.1 Market Overview
 - 6.2.2 Drug Delivery
 - 6.2.3 Therapeutics
 - 6.2.4 Vaccine Ingredient
 - 6.2.5 Culture Media Diagnostics
 - 6.3 Global Albumin Market (2018-2034) by End User
 - 6.3.1 Market Overview
 - 6.3.2 Hospitals & Clinics
 - 6.3.3 Pharmaceutical & Biotechnology Industry
 - 6.3.4 Research Institutes
 - 6.4 Global Albumin Market (2018-2034) by Region
 - 6.4.1 Market Overview
 - 6.4.2 North America
 - 6.4.3 Europe
 - 6.4.4 Asia Pacific
 - 6.4.5 Latin America
 - 6.4.6 Middle East and Africa
- 7 North America Albumin Market (218-2034)
 - 7.1 North America Albumin Market (2018-2034) by Product
 - 7.1.1 Market Overview
 - 7.1.2 Human Serum Albumin
 - 7.1.3 Recombinant Albumin
 - 7.1.4 Bovine Serum Albumin
 - 7.2 North America Albumin Market (2018-2034) by Application
 - 7.2.1 Market Overview
 - 7.2.2 Drug Delivery
 - 7.2.3 Therapeutics
 - 7.2.4 Vaccine Ingredient
 - 7.2.5 Culture Media Diagnostics
 - 7.3 North America Albumin Market (2018-2034) by Country
 - 7.3.1 United States of America
 - 7.3.2 Canada
- 8 Europe Albumin Market (218-2034)
 - 8.1 Europe Albumin Market (2018-2034) by Product
 - 8.1.1 Market Overview
 - 8.1.2 Human Serum Albumin
 - 8.1.3 Recombinant Albumin

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1.4 Bovine Serum Albumin
- 8.2 Europe Albumin Market (2018-2034) by Application
 - 8.2.1 Market Overview
 - 8.2.2 Drug Delivery
 - 8.2.3 Therapeutics
 - 8.2.4 Vaccine Ingredient
 - 8.2.5 Culture Media Diagnostics
- 8.3 Europe Albumin Market (2018-2034) by Country
 - 8.3.1 United Kingdom
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 Italy
 - 8.3.5 Others
- 9 Asia Pacific Albumin Market (2018-2034)
 - 9.1 Asia Pacific Albumin Market (2018-2034) by Product
 - 9.1.1 Market Overview
 - 9.1.2 Human Serum Albumin
 - 9.1.3 Recombinant Albumin
 - 9.1.4 Bovine Serum Albumin
 - 9.2 Asia Pacific Albumin Market (2018-2034) by Application
 - 9.2.1 Market Overview
 - 9.2.2 Drug Delivery
 - 9.2.3 Therapeutics
 - 9.2.4 Vaccine Ingredient
 - 9.2.5 Culture Media Diagnostics
 - 9.3 Asia Pacific Albumin Market (2018-2034) by Country
 - 9.3.1 China
 - 9.3.2 Japan
 - 9.3.3 India
 - 9.3.4 ASEAN
 - 9.3.5 Australia
 - 9.3.6 Others
- 10 Latin America Albumin Market (2018-2034)
 - 10.1 Latin America Albumin Market (2018-2034) by Product
 - 10.1.1 Market Overview
 - 10.1.2 Human Serum Albumin
 - 10.1.3 Recombinant Albumin
 - 10.1.4 Bovine Serum Albumin
 - 10.2 Latin America Albumin Market (2018-2034) by Application
 - 10.2.1 Market Overview
 - 10.2.2 Drug Delivery
 - 10.2.3 Therapeutics
 - 10.2.4 Vaccine Ingredient
 - 10.2.5 Culture Media Diagnostics
 - 10.3 Latin America Albumin Market (2018-2034) by Country
 - 10.3.1 Brazil
 - 10.3.2 Argentina

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Albumin Market (218-2034)
 - 11.1 Middle East and Africa Albumin Market (2018-2034) by Product
 - 11.1.1 Market Overview
 - 11.1.2 Drug Delivery
 - 11.1.3 Therapeutics
 - 11.1.4 Vaccine Ingredient
 - 11.1.5 Culture Media Diagnostics
 - 11.2 Middle East and Africa Albumin Market (2018-2034) by Application
 - 11.2.1 Market Overview
 - 11.2.2 Drug Delivery
 - 11.2.3 Therapeutics
 - 11.2.4 Vaccine Ingredient
 - 11.2.5 Culture Media Diagnostics
 - 11.3 Middle East and Africa Albumin Market (2018-2034) by Country
 - 11.3.1 Saudi Arabia
 - 11.3.2 United Arab Emirates
 - 11.3.3 Nigeria
 - 11.3.4 South Africa
 - 11.3.5 Others
- 12 Regulatory Framework
 - 12.1 Regulatory Overview
 - 12.1.1 US FDA
 - 12.1.2 EU EMA
 - 12.1.3 India CDSCO
 - 12.1.4 Japan PMDA
 - 12.1.5 Others
- 13 Patent Analysis
 - 13.1 Analysis by Type of Patent
 - 13.2 Analysis by Publication Year
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Patent Age
 - 13.5 Analysis by CPC Analysis
 - 13.6 Analysis by Patent Valuation
 - 13.7 Analysis by Key Players
- 14 Grants Analysis
 - 14.1 Analysis by Year
 - 14.2 Analysis by Amount Awarded
 - 14.3 Analysis by Issuing Authority
 - 14.4 Analysis by Grant Application
 - 14.5 Analysis by Funding Institute
 - 14.6 Analysis by NIH Departments
 - 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
 - 15.1 Analysis by Funding Instances
 - 15.2 Analysis by Type of Funding

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Partnership
 - 16.3 Analysis by Leading Players
 - 16.4 Analysis by Geography
- 17 Supplier Landscape
 - 17.1 Albumedix
 - 17.1.1 Company Overview
 - 17.1.2 Product Portfolio
 - 17.1.3 Demographic Reach and Achievements
 - 17.1.4 Mergers and Acquisitions
 - 17.1.5 Certifications
 - 17.2 Albumin Therapeutics, LLC
 - 17.2.1 Company Overview
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
 - 17.3 Biotest AG
 - 17.3.1 Company Overview
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisitions
 - 17.3.5 Certifications
 - 17.4 CSL
 - 17.4.1 Company Overview
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisitions
 - 17.4.5 Certifications
 - 17.5 Grifols, S.A.
 - 17.5.1 Company Overview
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisitions
 - 17.5.5 Certifications
 - 17.6 HiMedia Laboratories
 - 17.6.1 Company Overview
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisitions
 - 17.6.5 Certifications
 - 17.7 Invitria

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.7.1 Company Overview
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Medxbio Pte Ltd.
- 17.8.1 Company Overview
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Octapharma AG
- 17.9.1 Company Overview
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 RayBiotech, Inc.
- 17.10.1 Company Overview
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 SeraCare
- 17.11.1 Company Overview
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Merck KGaA
- 17.12.1 Company Overview
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Takeda Pharmaceutical Company Limited
- 17.13.1 Company Overview
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Kedrion S.p.A a
- 17.14.1 Company Overview
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.15 Aspira

17.15.1 Company Overview

17.15.2 Product Portfolio

17.15.3 Demographic Reach and Achievements

17.15.4 Mergers and Acquisitions

17.15.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Albumin Market Report and Forecast 2025-2034

Market Report | 2025-07-29 | 350 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4949.00
	Five User License	\$5949.00
	Corporate License	\$6969.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com